Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
An antiepileptic indicated in partial-onset epileptic seizures (EMA2107, FDA 2014).
Off-label it is used to treat neuropathic pain, fibromyalgia, osteoarthritis and migraine prophylaxis (Alcántara 2016, Moulin 2014, Gómez 2014), although with disputed evidence of its effectiveness (Wiffen 2013, McCleane 2013). Oral administration twice a day.
Its pharmacokinetic data (low molecular weight, low protein binding, high pKa) explains the potentially significant amounts transferred to breastmilk, with a very high relative dose, from 14% to 19% (Landmark 2021, Zárubová 2016).
However, other authors have found minimal excretion in the breastmilk of a mother who took lacosamide and levetiracetam throughout pregnancy and at the beginning of breastfeeding, with a relative dose of 1.8%. The mother stopped breastfeeding at 15 days due to drowsiness and insufficient feeding in the infant, who was born premature at 36 weeks, although the plasma levels in the infant were very low. At 7 months the infant showed good psychomotor development (Ylikotila 2015).
No problems of somatic or psychomotor development were observed at 18, 24 and 36 months of age in three infants whose mothers took lacosamide at doses of 300 and 400 mg/day in mono or polytherapy for 7, 8 and 9 months. Levels were not measured in milk or in the infants (Lattanzi 2017).
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Given the strength of existing evidence on the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to evaluate the risk-benefit of this medication, advising mothers who wish to continue breastfeeding on an individual basis (Crettenand 2018).
See below the information of this related product: